Perspective Therapeutics, Inc. (NYSE:CATX) Receives $19.00 Consensus Target Price from Analysts

Perspective Therapeutics, Inc. (NYSE:CATXGet Free Report) has earned an average recommendation of “Buy” from the six ratings firms that are currently covering the firm, MarketBeat reports. Six investment analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have covered the stock in the last year is $19.00.

CATX has been the subject of a number of recent analyst reports. Oppenheimer reaffirmed an “outperform” rating on shares of Perspective Therapeutics in a research note on Tuesday, June 18th. Lifesci Capital reiterated an “outperform” rating on shares of Perspective Therapeutics in a report on Monday, May 6th. Royal Bank of Canada restated an “outperform” rating and set a $30.00 price objective on shares of Perspective Therapeutics in a research report on Friday, June 14th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Perspective Therapeutics in a report on Tuesday, June 25th. Finally, B. Riley raised their price target on shares of Perspective Therapeutics from $12.00 to $17.00 and gave the stock a “buy” rating in a report on Tuesday, April 9th.

Get Our Latest Stock Analysis on Perspective Therapeutics

Perspective Therapeutics Trading Down 3.2 %

Shares of NYSE CATX opened at $10.61 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 12.98 and a current ratio of 12.98. Perspective Therapeutics has a 12 month low of $2.05 and a 12 month high of $19.05.

Perspective Therapeutics (NYSE:CATXGet Free Report) last announced its earnings results on Wednesday, May 15th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.10. The firm had revenue of $0.33 million during the quarter. On average, equities research analysts anticipate that Perspective Therapeutics will post -1 EPS for the current fiscal year.

Insider Transactions at Perspective Therapeutics

In other news, Director Robert F. Williamson III purchased 3,003 shares of the stock in a transaction that occurred on Wednesday, May 29th. The stock was acquired at an average price of $13.30 per share, with a total value of $39,939.90. Following the purchase, the director now owns 36,879 shares in the company, valued at approximately $490,490.70. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Perspective Therapeutics news, Director Robert F. Williamson III acquired 3,003 shares of the firm’s stock in a transaction that occurred on Wednesday, May 29th. The stock was purchased at an average cost of $13.30 per share, for a total transaction of $39,939.90. Following the completion of the acquisition, the director now owns 36,879 shares of the company’s stock, valued at approximately $490,490.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Johan M. Spoor purchased 10,000 shares of the firm’s stock in a transaction dated Thursday, June 13th. The shares were bought at an average price of $11.70 per share, with a total value of $117,000.00. Following the purchase, the chief executive officer now owns 13,757 shares in the company, valued at approximately $160,956.90. The disclosure for this purchase can be found here. Insiders bought 30,814 shares of company stock valued at $385,487 in the last three months. Corporate insiders own 3.52% of the company’s stock.

Hedge Funds Weigh In On Perspective Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. HighTower Advisors LLC acquired a new stake in shares of Perspective Therapeutics in the third quarter worth $314,000. Taylor & Morgan Wealth Management LLC raised its holdings in Perspective Therapeutics by 8.7% in the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock worth $251,000 after acquiring an additional 50,000 shares during the period. Vanguard Group Inc. lifted its position in Perspective Therapeutics by 34.6% during the 1st quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock worth $21,158,000 after acquiring an additional 4,566,356 shares during the last quarter. Virtu Financial LLC bought a new stake in Perspective Therapeutics during the first quarter valued at about $138,000. Finally, Janus Henderson Group PLC acquired a new stake in shares of Perspective Therapeutics in the first quarter valued at about $15,511,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

(Get Free Report

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

See Also

Analyst Recommendations for Perspective Therapeutics (NYSE:CATX)

Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.